Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDNNASDAQ:GNFTNASDAQ:NBRVNASDAQ:NGNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$3.41+9.6%$2.97$2.30▼$5.54$204.19M-0.16315,340 shs530,575 shsGNFTGENFIT$3.58-2.2%$4.14$2.55▼$6.42$179M1.0810,451 shs1,387 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs80 shsNGNENeurogene$20.18+3.5%$17.87$6.88▼$74.49$287.81M1.51250,335 shs29,020 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals+3.49%+14.76%+0.97%+14.76%+24.90%GNFTGENFIT-3.51%-1.05%-11.37%+9.70%-11.39%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%NGNENeurogene-2.72%+30.43%-10.67%+165.67%-42.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals2.5557 of 5 stars3.54.00.00.00.01.70.0GNFTGENFIT1.9822 of 5 stars3.54.00.00.00.00.00.0NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANGNENeurogene3.7731 of 5 stars4.43.00.00.01.82.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 3.00Buy$9.00163.93% UpsideGNFTGENFIT 3.00Buy$13.00263.13% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/ANGNENeurogene 2.75Moderate Buy$46.17128.77% UpsideCurrent Analyst Ratings BreakdownLatest NBRV, NGNE, GNFT, and ELDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.006/17/2025NGNENeurogeneCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.006/12/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.00 ➝ $26.005/20/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $22.005/16/2025NGNENeurogeneBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$38.00 ➝ $24.005/13/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.004/14/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $16.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.98 per shareN/AGNFTGENFIT$76.77M2.33$0.06 per share55.33$1.50 per share2.39NBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00NGNENeurogene$925K311.14N/AN/A$20.89 per share0.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$36.18M-$2.10N/AN/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ANGNENeurogene-$75.14M-$4.35N/AN/AN/AN/A-36.16%-32.51%8/8/2025 (Estimated)Latest NBRV, NGNE, GNFT, and ELDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A5/9/2025Q1 2025NGNENeurogene-$1.05-$1.08-$0.03-$1.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A13.9013.91GNFTGENFIT0.081.231.23NBRVNabriva Therapeutics0.120.850.52NGNENeurogeneN/A21.0321.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%GNFTGENFIT2.24%NBRVNabriva Therapeutics0.27%NGNENeurogene52.37%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals12.30%GNFTGENFIT4.20%NBRVNabriva Therapeutics1.63%NGNENeurogene11.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableNGNENeurogene9014.26 million12.85 millionOptionableNBRV, NGNE, GNFT, and ELDN HeadlinesRecent News About These CompaniesNeurogene Inc. (NASDAQ:NGNE) Receives $46.17 Average Price Target from BrokeragesJuly 6 at 2:09 AM | americanbankingnews.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 5 at 10:20 AM | morningstar.comMNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business WireJuly 5 at 10:20 AM | businesswire.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | businesswire.comNeurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 3, 2025 | marketbeat.comNeurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - MorningstarJuly 2, 2025 | morningstar.comMNeurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business WireJuly 2, 2025 | businesswire.comStifel maintient sa recommandation d’achat sur l’action NeurogeneJuly 2, 2025 | fr.investing.comNeurogene Inc. dévoile le protocole de l'étude Embolden(TM) sur la thérapie génique NGN-401 pour le syndrome de RettJuly 1, 2025 | zonebourse.comZLa FDA approuve le design d’essai clinique de Neurogene pour sa thérapie génique contre le syndrome de RettJune 30, 2025 | fr.investing.comNeurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett SyndromeJune 30, 2025 | businesswire.comCompanies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In GrowthJune 19, 2025 | finance.yahoo.comCraig-Hallum initiates Neurogene stock with buy rating on Rett therapyJune 18, 2025 | uk.investing.comCraig-Hallum bullish on Neurogene, initiates with a BuyJune 18, 2025 | finance.yahoo.comNeurogene (NASDAQ:NGNE) Coverage Initiated at Craig HallumJune 17, 2025 | marketbeat.comNeurogene (NGNE) Gets a Buy from BMO CapitalJune 14, 2025 | theglobeandmail.comNeurogene (NGNE) Gets a Buy from TD CowenJune 14, 2025 | theglobeandmail.comNeurogene price target raised to $26 from $22 at BMO CapitalJune 13, 2025 | investing.comNeurogene (NASDAQ:NGNE) Given New $26.00 Price Target at BMO Capital MarketsJune 12, 2025 | marketbeat.comL’objectif de prix de Neurogene relevé à 26€ contre 22€ par BMO CapitalJune 11, 2025 | fr.investing.comTwo Sigma Investments LP Invests $472,000 in Neurogene Inc. (NASDAQ:NGNE)June 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBRV, NGNE, GNFT, and ELDN Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$3.41 +0.30 (+9.65%) As of 01:05 PM EasternEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.GENFIT NASDAQ:GNFT$3.58 -0.08 (-2.19%) As of 01:03 PM EasternGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Neurogene NASDAQ:NGNE$20.18 +0.68 (+3.49%) As of 01:08 PM EasternNeurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
